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Abstract
Acute lung injury is a syndrome of inflammation and of increased
permeability of the blood–gas barrier. Endothelins are thought to
exert proinflammatory effects. Kuklin and colleagues show that the
endothelin receptor antagonist tezosentan reduces pulmonary
edema in endotoxemic sheep, in parallel with a prevention of
protein kinase C-α activation. In turn, the level of some cytokines
increased after tezosentan treatment. Whether these contrasting
effects of endothelin blockade on inflammatory mechanisms have
clinical relevance and whether these agents might benefit patients
with acute lung injury is unknown.
In the search for new agents to protect the lung from injury,
Kuklin and colleagues [1] report that tezosentan, a non-
selective endothelin-1 receptor antagonist, reduces pulmonary
edema in endotoxemic sheep, in parallel with a prevention of
protein kinase C-α activation.
Mechanisms of acute lung injury
Acute lung injury (ALI) and its more severe form, acute
respiratory distress syndrome (ARDS), are syndromes of
acute respiratory failure secondary to permeability, non-
cardiogenic, pulmonary edema. Common causes are sepsis,
pneumonia, aspiration and trauma. ALI/ARDS is a major
cause of morbidity, death and cost in intensive care units
[2,3]. Alveolar edema accumulates in ALI/ARDS mainly
because the permeability of the capillary (endothelium)–
alveolar (epithelium) barrier is increased. This mechanism
allows edema formation at normal capillary pressures and
greatly increases the rate of edema formation at elevated
capillary pressures [2,3]. In addition, pressure elevation in the
pulmonary circulation and mechanical stresses applied to the
lung (during mechanical ventilation, for example) may cause
“stress failure” in lung capillaries and alveoli, as evident in the
formation of breaks and discontinuities in the endothelial and
epithelial membranes of the blood–gas barrier [4].
The American–European consensus conference on ARDS
defined ALI/ARDS as a “syndrome of inflammation and
increased permeability”. Hence, it is now widely accepted
that the pathophysiology of ALI/ARDS is driven by an
aggressive inflammatory reaction that damages the alveolo-
capillary unit [2,3,5,6]. The inflammatory response includes
both cellular and humoral components. After rapid recruit-
ment of leukocytes to the inflamed site, there is activation of
mediator cascades including the production of cytokines,
chemokines, acute phase proteins, free radicals, complement,
coagulation pathway components and focal upregulation of
adhesion molecule expression units [5,6]. Several cytokines,
such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1,
IL-6 and IL-8, have been found in bronchoalveolar lavage fluid
and plasma of patients with ARDS [3,5]. Inflammatory
mediators amplify endothelial injury directly or by recruiting
inflammatory cells into the vascular, interstitial and alveolar
spaces [3,5].
In addition, some mediators may also alter endothelial
permeability by disturbing intracellular signaling pathways.
TNF-α and α-thrombin have been shown to activate protein
kinase C-mediated mechanisms that participate in the
pulmonary endothelial response to agents involved in lung
injury [3,7]. Protein kinase C is a ubiquitously expressed
family of kinases that have a key role in regulating multiple
cellular activities. Activation of specific protein kinase C
isoforms, most probably protein kinase C-α, may cause lung
endothelial dysfunction through several mechanisms [1,3,7].
Endothelins and inflammation
Endothelins are a family of 21-amino-acid isopeptides. Initially
described as strong vasoconstrictors, endothelins are now
believed also to exert potent proinflammatory effects. For
example, transgenic mice overexpressing endothelin-1
release increased amounts of TNF-α, interferon-γ, IL-1 and
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IL-6 [8]. The endothelin system is activated in clinical lung
injury and in various types of experimental lung injury [9], and
several endothelin receptor antagonists have been reported
to exert protective effects in some models of ALI/ARDS [10].
Endothelins may thus play a pathophysiologic role in
ALI/ARDS and promote pulmonary edema by increasing the
filtration pressure (as postcapillary vasoconstrictors), and
also by increasing capillary permeability (as inflammatory
mediators). The results of Kuklin and colleagues [1] are in
accordance with this hypothesis and provide further insight
into an intracellular effect of endothelin receptor antagonists
(i.e. prevention of protein kinase C-α activation).
Endothelin receptor antagonists have been made available
recently for clinical use in the treatment of pulmonary arterial
hypertension [11]. These drugs may therefore offer new and
attractive opportunities for the management of patients with
ALI/ARDS, especially because, to date, no pharmacologic
agent has been convincingly shown to improve the prognosis
of these patients [12]. The data of Kuklin and colleagues [1]
suggest that endothelin receptor antagonists might benefit
patients with ALI/ARDS.
There is, however, the other side of the coin. As expected from
the use of a receptor antagonist, the level of the ligand
increased; that is, the plasma concentration of endothelin-1
was elevated after tezosentan treatment [1]. As also expected
from the proinflammatory properties of endothelin-1 [8], plasma
levels of TNF-α and IL-8 increased after tezosentan treatment
[1]. The clinical relevance of these observations is unknown,
but production of these cytokines might counteract the benefits
expected from endothelin blockade. In other experimental
models of ALI/ARDS, endothelin receptor antagonists did not
decrease intrapulmonary shunt [13], lung lymph flow or the
histologically evaluated degree of parenchymal injury [14],
despite a reduction in pulmonary vascular resistance.
Conclusion
The work of Kuklin and colleagues [1] provides important
information on the complex effects of endothelin blockers on
inflammatory processes. From a clinical point of view, given
the prolific nature of the inflammatory cascade causing
ALI/ARDS and the angel/devil effects of endothelin receptor
antagonists on inflammatory mechanisms, it is unlikely that
these single agents could reverse or terminate such a
complex process [12].
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